KR102547164B1 - 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법 - Google Patents

특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법 Download PDF

Info

Publication number
KR102547164B1
KR102547164B1 KR1020227009418A KR20227009418A KR102547164B1 KR 102547164 B1 KR102547164 B1 KR 102547164B1 KR 1020227009418 A KR1020227009418 A KR 1020227009418A KR 20227009418 A KR20227009418 A KR 20227009418A KR 102547164 B1 KR102547164 B1 KR 102547164B1
Authority
KR
South Korea
Prior art keywords
subject
apoe4
pharmaceutical composition
tramiprosate
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227009418A
Other languages
English (en)
Korean (ko)
Other versions
KR20220042480A (ko
Inventor
수잔 아부샤크라
에이단 파워
마틴 톨라
존 헤이
제레미 유
페트르 코시스
Original Assignee
알제온, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102547164(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알제온, 인크. filed Critical 알제온, 인크.
Publication of KR20220042480A publication Critical patent/KR20220042480A/ko
Application granted granted Critical
Publication of KR102547164B1 publication Critical patent/KR102547164B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227009418A 2015-09-10 2016-09-09 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법 Active KR102547164B1 (ko)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US62/216,404 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US62/290,287 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US62/302,027 2016-03-01
US201662365809P 2016-07-22 2016-07-22
US62/365,809 2016-07-22
PCT/US2016/051091 WO2017044840A1 (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population
KR1020187009381A KR102412997B1 (ko) 2015-09-10 2016-09-09 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187009381A Division KR102412997B1 (ko) 2015-09-10 2016-09-09 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법

Publications (2)

Publication Number Publication Date
KR20220042480A KR20220042480A (ko) 2022-04-05
KR102547164B1 true KR102547164B1 (ko) 2023-06-22

Family

ID=58240195

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227009418A Active KR102547164B1 (ko) 2015-09-10 2016-09-09 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
KR1020187009381A Active KR102412997B1 (ko) 2015-09-10 2016-09-09 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187009381A Active KR102412997B1 (ko) 2015-09-10 2016-09-09 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법

Country Status (21)

Country Link
US (3) US11191742B2 (enExample)
EP (2) EP3347002B1 (enExample)
JP (4) JP6789579B2 (enExample)
KR (2) KR102547164B1 (enExample)
CN (3) CN116712422A (enExample)
AU (1) AU2016319107B2 (enExample)
CA (1) CA2997376C (enExample)
DK (1) DK3347002T3 (enExample)
ES (1) ES2952727T3 (enExample)
FI (1) FI3347002T3 (enExample)
HR (1) HRP20230809T1 (enExample)
HU (1) HUE062511T2 (enExample)
LT (1) LT3347002T (enExample)
MD (1) MD3347002T2 (enExample)
MX (2) MX392677B (enExample)
PL (1) PL3347002T3 (enExample)
PT (1) PT3347002T (enExample)
RS (1) RS64481B1 (enExample)
SI (1) SI3347002T1 (enExample)
SM (1) SMT202300250T1 (enExample)
WO (1) WO2017044840A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2941415A1 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
KR102547164B1 (ko) * 2015-09-10 2023-06-22 알제온, 인크. 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
CN108623501B (zh) 2017-03-21 2022-04-19 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸衍生物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
CN112867485A (zh) * 2018-08-01 2021-05-28 阿尔泽恩股份有限公司 用于治疗神经变性病症的方法
JP7466520B2 (ja) * 2018-08-01 2024-04-12 アルツェオン・インコーポレーテッド 神経変性障害を治療するためのスルホプロパン酸誘導体
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
WO2020257159A1 (en) 2019-06-17 2020-12-24 Alzheon, Inc. Methods for treating neurodegenerative disorders
CN112791078B (zh) 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
KR20240116529A (ko) * 2021-12-09 2024-07-29 알제온, 인크. 알츠하이머병 치료에 사용하기 위한 alz-801
EP4475831A1 (en) * 2022-02-07 2024-12-18 Alzheon, Inc. Alz-801 for use in treating a covid-19 associated neurological symptom

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120071468A1 (en) 2010-08-19 2012-03-22 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders
US20140220122A1 (en) 2006-10-12 2014-08-07 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
DE625212T1 (de) 1992-10-13 2000-11-02 Duke University, Durham Verfahren zum entdecken von krankheit von alzheimer.
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2007502418A (ja) 2003-08-11 2007-02-08 カリフォルニア・インスティテュート・オブ・テクノロジー 微量流体大規模集積
US20060257480A1 (en) * 2005-04-12 2006-11-16 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
MX2009005279A (es) 2006-11-24 2009-05-28 Ac Immune Sa Derivados de n-(metil)-1h-pirazol-3-amina, n-(metil)-piridin-2-ami na y n-(metil)-tiazol-2-amina para el tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide, tal como por ejemplo alzheimer.
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
WO2012006329A2 (en) 2010-07-06 2012-01-12 Genomind, Llc Apoe4 and apoj biomarker-based prevention and treatment of dementia
US20150118231A1 (en) * 2012-05-08 2015-04-30 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
PT2994160T (pt) * 2013-05-06 2019-08-07 Baxalta Inc Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada
EP3718563A1 (en) * 2014-02-08 2020-10-07 F. Hoffmann-La Roche AG Methods of treating alzheimer's disease
CA2941415A1 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
KR102547164B1 (ko) * 2015-09-10 2023-06-22 알제온, 인크. 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140220122A1 (en) 2006-10-12 2014-08-07 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US20120071468A1 (en) 2010-08-19 2012-03-22 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders

Also Published As

Publication number Publication date
KR20220042480A (ko) 2022-04-05
FI3347002T3 (fi) 2023-08-10
US20220096406A1 (en) 2022-03-31
AU2016319107B2 (en) 2021-02-25
US11191742B2 (en) 2021-12-07
CN116712423A (zh) 2023-09-08
AU2016319107A1 (en) 2018-03-22
CN108289870A (zh) 2018-07-17
EP3347002A4 (en) 2019-04-24
KR20180051561A (ko) 2018-05-16
KR102412997B1 (ko) 2022-06-23
JP7128536B2 (ja) 2022-08-31
JP6789579B2 (ja) 2020-11-25
CA2997376C (en) 2024-05-14
WO2017044840A1 (en) 2017-03-16
JP2018526407A (ja) 2018-09-13
SMT202300250T1 (it) 2023-09-06
SI3347002T1 (sl) 2023-12-29
EP3347002B1 (en) 2023-06-07
PL3347002T3 (pl) 2023-11-13
LT3347002T (lt) 2023-09-11
EP3347002A1 (en) 2018-07-18
CN116712422A (zh) 2023-09-08
RS64481B1 (sr) 2023-09-29
HUE062511T2 (hu) 2023-11-28
CA2997376A1 (en) 2017-03-16
US20230414541A1 (en) 2023-12-28
JP2022145949A (ja) 2022-10-04
HK1257874A1 (en) 2019-11-01
EP4275750A3 (en) 2024-01-17
MD3347002T2 (ro) 2023-10-31
DK3347002T3 (da) 2023-08-14
HRP20230809T1 (hr) 2023-10-27
ES2952727T3 (es) 2023-11-03
MX2022003128A (es) 2022-08-02
MX2018003023A (es) 2018-06-06
MX392677B (es) 2025-03-24
JP2020200352A (ja) 2020-12-17
EP4275750A2 (en) 2023-11-15
PT3347002T (pt) 2023-07-27
JP2025065545A (ja) 2025-04-17

Similar Documents

Publication Publication Date Title
KR102547164B1 (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
KR101918669B1 (ko) 신경 장애 치료용 신규 조성물
US10639314B1 (en) Method of treating Alzheimer's disease
US11690849B2 (en) Method of treating dementia
WO2020222799A1 (en) A method of treating mental, behavioral, cognitive disorders
JP2022514152A (ja) Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
US20180250249A1 (en) Methods of treating neurodegenerative disorders in a particular population
US20230414567A1 (en) Methods of treating conditions related to the s1p1 receptor
HK40094581A (en) Treatment of alzheimer's disease in a particular patient population
HK1257874B (en) Treatment of alzheimer's disease in a particular patient population
AU2018258970B2 (en) Idalopirdine-based combinatorial therapies of Alzheimer's disease
WO2023214312A1 (en) Methods of treating atopic dermatitis with etrasimod
US20140243342A1 (en) Compositions and methods for prophylaxis and therapy for menieres disease

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220322

Application number text: 1020187009381

Filing date: 20180403

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220420

Comment text: Request for Examination of Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230320

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230620

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230620

End annual number: 3

Start annual number: 1

PG1601 Publication of registration